EUVIMEDEUVIMED entdecken
Crossref

Elevated insulin‐like growth factor‐1 in patients without clinical evidence of acromegaly

Laura Careless, Warrick J Inder iD, Carel Pretorius, Lisa Hayes iD

Clinical Endocrinology · 2023

DOI: 10.1111/cen.14917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2023. Verfasst von Laura Careless und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Acromegaly, Human Growth Hormone. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To (1) identify the frequency of IGF‐1 elevation in a cohort of patients without clinically suspected GH excess, in a state‐based reference laboratory over a 24‐month period, and (2) to examine potential differences in comorbidities and relevant medications between people with an elevated IGF‐1 compared to a matched control group.

Design

All IGF‐1 measurements at Pathology Queensland between 1/12/2018–1/12/2020 were identified. The medical records of those with IGF‐1 ≥1.1x the upper limit of the reference range were appraised to determine: (1) documentation of acromegalic features, (2) relevant comorbidities and medication use, and (3) further investigations to exclude pathological GH excess. Patients and Measurements There were 2759 IGF‐1 samples measured in 1963 people ≥18 years, over the specified period. Of these, 204 had IGF‐1 ≥1.1x the upper limit of the age‐matched reference range; 102 cases (61M, 41F) met inclusion criteria, and were matched to 102 controls with a normal IGF‐1 based on age, sex, gonadal status and pituitary anatomy on MRI.

Results

There were significant differences in the frequency of dopamine agonist use (19/102 cases vs. 6/102 controls, OR = 3.66, 95% confidence interval [CI]: 1.45–9.29, p = .009) and chronic kidney disease (CKD) (14/102 cases vs. 4/102 controls, OR = 3.90, 95% CI: 1.28–11.14, p = .024).

Conclusions

Out of 1963 patients having IGF‐1 measured, 102 (5.2%) had an elevated IGF‐1 where there was no known acromegaly, GH replacement or endogenous glucocorticoid excess. Intraindividual biological variability, assay imprecision and physiological factors are known contributors to falsely elevated IGF‐1, dopamine agonist therapy and CKD should also be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyHuman Growth HormoneHumansInsulin-Like Growth Factor IDopamine AgonistsPituitary Gland

Stichwörter der Autor:innen

IGF-1acromegaly

Substanzen

Human Growth HormoneInsulin-Like Growth Factor IDopamine Agonists

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
  • Academy for Medical Education, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

ORCID-Profile: Warrick J Inder, Lisa Hayes

Zitieren

APA

Careless, L., Inder, W. J., Pretorius, C., & Hayes, L. (2023). Elevated insulin‐like growth factor‐1 in patients without clinical evidence of acromegaly. Clinical Endocrinology. https://doi.org/10.1111/cen.14917

Vancouver

Careless L, Inder WJ, Pretorius C, Hayes L. Elevated insulin‐like growth factor‐1 in patients without clinical evidence of acromegaly. Clinical Endocrinology. 2023. doi:10.1111/cen.14917

BibTeX
@article{Careless2023,
  author = {Careless, Laura and Inder, Warrick J and Pretorius, Carel and Hayes, Lisa},
  title = {Elevated insulin‐like growth factor‐1 in patients without clinical evidence of acromegaly},
  journal = {Clinical Endocrinology},
  year = {2023},
  doi = {10.1111/cen.14917}
}
Kostenlos starten →